The Combination of Radiotherapy and Complement C3a Inhibition Potentiates Natural Killer cell Functions Against Pancreatic Cancer

Pancreatic cancer is one of the deadliest cancers, against which current immunotherapy strategies are not effective. Herein, we analyzed the immune cell composition of the tumor microenvironment of pancreatic cancer samples in The Cancer Genome Atlas and found that the presence of intratumoral natural killer (NK) cells correlates with survival. Subsequent analysis also indicated that NK cell exclusion from the microenvironment is found in a high percentage of clinical pancreatic cancers and in preclinical models of pancreatic cancer. Mechanistically, NK cell exclusion is regulated in part by complement C3a and its receptor signaling. Inhibition of the C3a receptor enhances NK cell infiltration in syngeneic mouse models of pancreatic cancer resulting in tumor growth delay. However, tumor growth inhibition mediated by NK cells is not sufficient alone for complete tumor regression, but is potentiated when combined with radiotherapy. Our findings indicate that although C3a inhibition is a promising approach to enhance NK cell–based immunotherapy against pancreatic cancer, its combination with radiotherapy holds greater therapeutic benefit. Significance: Immunotherapeutic agents are not effective against pancreatic cancer. We show that the inhibition of complement C3a enhances NK cell infiltration in preclinical models of pancreatic cancer, resulting in tumor growth delay. This effect is further potentiated by radiotherapy, thereby leading to significant antitumor activity compared with either therapy alone.

[1]  E. Graves,et al.  C3aR Signaling Inhibits NK-cell Infiltration into the Tumor Microenvironment in Mouse Models , 2021, Cancer Immunology Research.

[2]  E. Nakakura,et al.  Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[4]  D. Wainwright,et al.  NK cell-based cancer immunotherapy: from basic biology to clinical development , 2021, Journal of Hematology & Oncology.

[5]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[6]  Qiaofei Liu,et al.  Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Origin, Polarization, Function, and Reprogramming , 2021, Frontiers in Cell and Developmental Biology.

[7]  J. Boudreau,et al.  NK cell infiltration is associated with improved overall survival in solid cancers: A systematic review and meta-analysis , 2020, Translational oncology.

[8]  X. Lao,et al.  Worldwide Burden of, Risk Factors for, and Trends in Pancreatic Cancer. , 2020, Gastroenterology.

[9]  C. Robert A decade of immune-checkpoint inhibitors in cancer therapy , 2020, Nature Communications.

[10]  M. Karamouzis,et al.  Immunotherapy for pancreatic cancer: A 2020 update. , 2020, Cancer treatment reviews.

[11]  Cai Zhang,et al.  Targeting Natural Killer Cells for Tumor Immunotherapy , 2020, Frontiers in Immunology.

[12]  C. Pereira,et al.  Is immunotherapy the holy grail for pancreatic cancer? , 2019, Immunotherapy.

[13]  T. H. Nguyen,et al.  The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2019, The lancet. Gastroenterology & hepatology.

[14]  Vanessa M. Hubbard-Lucey,et al.  Immuno-oncology drug development goes global , 2019, Nature Reviews Drug Discovery.

[15]  J. Kos,et al.  Cysteine Cathepsins in Tumor-Associated Immune Cells , 2019, Front. Immunol..

[16]  S. Antonia,et al.  The NKG2A immune checkpoint — a new direction in cancer immunotherapy , 2019, Nature Reviews Clinical Oncology.

[17]  Ash A. Alizadeh,et al.  Determining cell-type abundance and expression from bulk tissues with digital cytometry , 2019, Nature Biotechnology.

[18]  C. Fisher,et al.  The adequacy of tissue microarrays in the assessment of inter- and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcoma , 2018, Scientific Reports.

[19]  A. Gonzalez-Perez,et al.  NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival , 2018, Clinical Cancer Research.

[20]  A. Koong,et al.  Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance , 2018, Scientific Reports.

[21]  Alexander H. E. Morrison,et al.  Immunotherapy and Prevention of Pancreatic Cancer. , 2018, Trends in cancer.

[22]  Ash A. Alizadeh,et al.  Profiling Tumor Infiltrating Immune Cells with CIBERSORT. , 2018, Methods in molecular biology.

[23]  E. Smits,et al.  CD56 in the Immune System: More Than a Marker for Cytotoxicity? , 2017, Front. Immunol..

[24]  P. Storm,et al.  Characterization of resident lymphocytes in human pancreatic islets , 2017, Clinical and experimental immunology.

[25]  A. Akbarzadeh,et al.  Prognostic implication of CD57, CD16, and TGF-β expression in oral squamous cell carcinoma. , 2016, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[26]  T. Sayers,et al.  NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype , 2015, The Journal of Immunology.

[27]  M. Okoniewski,et al.  Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response. , 2015, Immunity.

[28]  E. Golden,et al.  Radiotherapy and immunogenic cell death. , 2015, Seminars in radiation oncology.

[29]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[30]  P. Lapierre,et al.  Transient Complement Inhibition Promotes a Tumor-Specific Immune Response through the Implication of Natural Killer Cells , 2013, Cancer Immunology Research.

[31]  H. Klingemann Cellular therapy of cancer with natural killer cells-where do we stand? , 2013, Cytotherapy.

[32]  Cesar M. Castro,et al.  Targeting cathepsin E in pancreatic cancer by a small molecule allows in vivo detection. , 2013, Neoplasia.

[33]  W. Murphy,et al.  Advantages and clinical applications of natural killer cells in cancer immunotherapy , 2013, Cancer Immunology, Immunotherapy.

[34]  S. Demaria,et al.  The convergence of radiation and immunogenic cell death signaling pathways , 2012, Front. Oncol..

[35]  A. Cerwenka,et al.  Natural Killer Cells and Solid Tumors , 2011, Journal of Innate Immunity.

[36]  John D Lambris,et al.  Complement: a key system for immune surveillance and homeostasis , 2010, Nature Immunology.

[37]  Dale L. Greiner,et al.  Humanized mice in translational biomedical research , 2007, Nature Reviews Immunology.

[38]  K. Camphausen,et al.  Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy , 2006, The Journal of experimental medicine.

[39]  Eric J. Brown,et al.  The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor , 2005, Nature.

[40]  Jung‐Ta Chen,et al.  Prognostic significance of intratumoral natural killer cells in primary resected esophageal squamous cell carcinoma. , 2005, Chang Gung medical journal.

[41]  A. Concha,et al.  Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas , 2005, Cancer Immunology, Immunotherapy.

[42]  R. Figlin,et al.  Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  S. Coca,et al.  Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. , 2002, Lung cancer.

[44]  M. Giga,et al.  The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. , 2001, The Journal of thoracic and cardiovascular surgery.

[45]  J. Adams,et al.  Identification of a Selective Nonpeptide Antagonist of the Anaphylatoxin C3a Receptor That Demonstrates Antiinflammatory Activity in Animal Models , 2001, The Journal of Immunology.

[46]  S. Natsugoe,et al.  Prognostic value of intratumoral natural killer cells in gastric carcinoma , 2000, Cancer.

[47]  M. A. Sáez,et al.  The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma , 1997, Cancer.

[48]  A. Andoh,et al.  Local secretion of complement C3 in the exocrine pancreas: ductal epithelial cells as a possible biosynthetic site. , 1996, Gastroenterology.

[49]  F. Schabel,et al.  Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. , 1984, Cancer research.

[50]  R. Frade,et al.  Inhibition of in vitro natural killer activity by the third component of complement: role for the C3a fragment. , 1982, Proceedings of the National Academy of Sciences of the United States of America.